Jesduvroq

Jesduvroq is an oral HIF-PHI approved for the treatment of anemia in adults with chronic kidney disease on dialysis. It was voluntarily withdrawn in the U.S. for non-safety-related reasons but remains FDA-listed.

Molecule Details :

  • Molecule Name :

    Daprodustat
  • Innovator :

    GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
  • Approval Date :

    1-Feb-23
  • NCE-1 Date :

    1-Feb-27
  • Dosage Form :

    Tablet
  • Strength :

    1mg,2mg,4mg,6mg,8mg
  • Therapeutic Category :

    Antianemic
  • Revenue ($M) :

    83

Year-wise Projected Sales ($M) :

  • 2025 :

    170
  • 2026 :

    213
  • 2027 :

    249
  • 2028 :

    274
  • 2029 :

    294
  • 2030 :

    297
  • 2031 :

    305
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?